Connect your AI

Ligand Pharmaceuticals LGND Earnings yield

Earnings yield at other companies

Royalty PharmaRPRX

4%-4.1pp

LQD

Liquidia CorporationLQDA

-6.2%-2.3pp

RevvityRVTY

2.4%+0.2pp

BridgeBio PharmaBBIO

-5.1%-1.7pp

Roivant SciencesROIV

-5.4%-5.8pp

Relay Therapeutics, Inc.RLAY

-15.3%-6.8pp

Other financials

Income statement

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

Market cap$5.6B+96.7%

Profitability

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

net income/market cap=3.9%

Based on trailing twelve months.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ligand Pharmaceuticals's earnings yield?: Ligand Pharmaceuticals (LGND) reported earnings yield of 3.9% in Q1 2026.
How has Ligand Pharmaceuticals's earnings yield changed year-over-year?: Ligand Pharmaceuticals's earnings yield increased by 158.9% year-over-year, from -6.6% to 3.9%.
What is the long-term trend for Ligand Pharmaceuticals's earnings yield?: Over 5 years (2020 to 2025), Ligand Pharmaceuticals's earnings yield has grown at a 79.5% compound annual growth rate (CAGR), from -0.2% to 3.3%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.